苦碟子与依达拉奉联合应用于缺血性脑卒中患者中的效果及对骨保护素的作用

The Effect of Kudiezi Combined with Edaravone in Patients with Ischemic Stroke and Its Effect on Osteoprotegerin

目的探讨苦碟子与依达拉奉联合应用于缺血性脑卒中患者中的效果及对骨保护素(OPG)的作用。方法便利选择2018年1月—2019年12月该院收治的102例缺血性脑卒中患者作为研究对象。按随机数字表法将上述患者随机分为两组,对照组与研究组,各51例。两组应用常规对症治疗。同时,对照组应用依达拉奉注射液治疗,研究组在此基础上应用苦碟子注射液治疗。对比两组治疗的总有效率、治疗前后血清OPG水平,以及药物不良反应。结果研究组治疗的总有效率为90.20%高于对照组70.59%,差异有统计学意义(χ^(2)=6.220,P<0.05)。治疗后,研究组OPG水平(112.0±30.5)ng/L低于对照组(140.5±28.0)ng/L,差异有统计学意义(t=4.916,P<0.01)。两组治疗期间均未见明显的药物不良反应。结论苦碟子与依达拉奉联合应用于缺血性脑卒中患者中效果显著,并可以调节OPG水平,值得临床推广。

Objective To investigate the effect of Kudiezi combined with edaravone in patients with ischemic stroke and its effect on osteoprotegerin(OPG).Methods 102 patients with ischemic stroke admitted to the hospital from January 2018 to December 2019 were conveniently selected as the research objects.According to the random number table method,the above-mentioned patients were randomly divided into two groups,with 51 cases in each of the control group and the study group.The two groups were treated with conventional symptomatic treatment.At the same time,the control group was treated with edaravone injection,and the study group was treated with Kudiezi injection on this basis.The total effective rate of the two groups of treatment,serum OPG levels before and after treatment,and adverse drug reactions were compared.Results The total effective rate of treatment in the study group was 90.20%higher than that of the control group 70.59%,the difference was statistically significant(χ^(2)=6.220,P<0.05).After treatment,the OPG level of the study group(112.0±30.5)ng/L was lower than the control group(140.5±28.0)ng/L,the difference was statistically significant(t=4.916,P<0.01).There were not obvious adverse drug reactions in the two groups during treatment.Conclusion The combination of Kudiezi and edaravone in patients with ischemic stroke has a significant effect and can regulate OPG levels,which is worthy of clinical promotion.